Company
CNSX:BUZZ
PharmaDrug Inc is a specialty pharmaceutical company focused on the research, development and commercialization of controlled substances and natural medicines such as psychedelics and previously approved drugs. The company owns 51% of Sairiyo Therapeutics, a biotech company specialising in researching and reformulating established natural medicines to bring them through clinical trials and the associated regulatory approval process in the US and Europe.
66 stories · page 3 of 4
CEO Daniel Cohen said 'forthcoming feedback from the FDA' will provide 'critical information relevant to defining our parallel development paths for PharmaDrug's cepharanthine programs in both COVID-19 and rare cancers'
It said MycoWe℞ Infinite will be positioned as a premium brand in a rapidly growing marketplace that is primarily occupied by high price, low potency functional mushroom products
Daniel Cohen, chairman and CEO of PharmaDrug, commented: "David's unique combination of experience in big pharma, biotech and investment banking ideally suits PharmaDrug as it increasingly shifts its focus to a biotech strategy"
The clinical research collaboration builds upon its existing strategy of focusing on establishing a better understanding of the basic mechanisms by which DMT exerts its effects in the brain and elsewhere in the body
The two groups will develop the platform to transmit tryptamine-based pharmaceuticals such as DMT to treat eye diseases like glaucoma, the second-leading cause of blindness in the world
CEO Daniel Cohen told shareholders that the firm did not expect to see such significant growth inhibition in difficult-to-treat cancers
The pharmaceutical company announced it is changing its Canadian ticker symbol from ‘BUZZ’ to ‘PHRX’ to better align with its strategy
Data from 35 of the 60 cancer cell lines were reported to PharmaDrug, with 11 cancer cell lines showing the heightened response
The company believes that its novel formulation of cepharanthine, PD-001 would be an ideal candidate to evaluate as a potential treatment for mild-to-moderate COVID-19
The digital store will sell psilocybin truffles as well as functional mushrooms in the Netherlands, while the European market will have access to only the functional mushrooms
Visitors to the Slim Winkel e-commerce site will be treated to informative blogs and educational tips that will allow them to easily integrate the mushrooms into their lifestyle
The company said it will begin selling the THC product in Germany by September, one of several movers it is making to significantly increase its presence and volumes in the German medical cannabis market
Van Slyke previously served as the CSO on a consultancy basis of biotech and subsidiary Sairiyo Therapeutics, which PharmaDrug recently acquired
The study will look at the anti-cancer properties of the enteric-coated formulation of Cepharanthine known as PD-001 in a large panel of solid and liquid cancer cell types
The designation was granted to PharmaDrug’s subsidiary Sairiyo Therapeutics Inc and covers solid organ transplantation, which includes the liver, kidney, heart and lungs
In connection with its recent acquisition of Sairiyo Therapeutics, the company has secured an exclusive license to develop and commercialize a novel oral formulation
Borjigin has been studying DMT since 2012 and published seminal research, including the discovery of DMT production in the pineal gland of live rats
Rogosnitzky leads Drug Rediscovery Group Ltd in Rehovot, Israel, which focuses on the repurposing of generic drugs
An international expert in cancers of the esophagus and stomach, Janjigian is currently leading several studies that could impact the standard of care for cancers in these fields
DMT has been shown to have anti-inflammatory properties and potentially mitigates ischemia-reperfusion injury caused by hypoxia, oxidative stress and inflammation in preclinical models of renal transplantation
